<DOC>
	<DOCNO>NCT00327119</DOCNO>
	<brief_summary>The primary objective study assess effect treatment ABX-EGF best overall objective response rate modify RECIST ( confirm complete partial response ) Japanese subject metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase 2 Study ABX-EGF ( Panitumumab ) Japanese Subjects With M-colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic colorectal adenocarcinoma ; Subjects must become refractory treatment unable continue treatment due toxicity reason treatment fluoropyrimidine , irinotecan oxaliplatin metastatic colorectal cancer include relapse within 6 month completion adjuvant therapy use agent ; Tumor express EGFr level immunohistochemistry ( membrane staining must positive 1 % evaluated tumor cell ) . Subjects prior experimental approve antibody ( eg , bevacizumab ) within 3 month enrollment ; Subjects prior EGFr target agent ; Chemotherapy fluoropyrimidine ( include oral agent UFT , TS1 ) , irinotecan , oxaliplatin ( raltitrexed ) colorectal carcinoma accordance specify regimen ( leucovorin levamisole consider chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>EGFR</keyword>
	<keyword>Fully human</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>ABX-EGF</keyword>
	<keyword>AMG954</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Japan</keyword>
</DOC>